HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

H Yagita Selected Research

KB R7785

11/2000Effect of a matrix metalloproteinase inhibitor on host resistance against Listeria monocytogenes infection.
8/2000A metalloproteinase inhibitor prevents acute graft-versus-host disease while preserving the graft-versus-leukaemia effect of allogeneic bone marrow transplantation.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown:


H Yagita Research Topics

Disease

19Neoplasms (Cancer)
06/2013 - 01/2000
9Inflammation (Inflammations)
09/2014 - 08/2000
6Necrosis
01/2009 - 05/2001
5Graft vs Host Disease (Graft-Versus-Host Disease)
01/2015 - 04/2000
5Leukemia
03/2013 - 08/2000
5Experimental Autoimmune Encephalomyelitis (Encephalomyelitis, Autoimmune Experimental)
11/2012 - 01/2000
5Autoimmune Diseases (Autoimmune Disease)
10/2007 - 01/2000
4Type 1 Diabetes Mellitus (Autoimmune Diabetes)
05/2006 - 03/2000
3Asthma (Bronchial Asthma)
09/2014 - 01/2009
3Neoplasm Metastasis (Metastasis)
11/2009 - 01/2001
3Allergic Conjunctivitis (Giant Papillary Conjunctivitis)
01/2009 - 08/2006
3Autoimmune Thyroiditis (Lymphomatous Thyroiditis)
12/2008 - 02/2001
2Acute Myeloid Leukemia (Acute Myelogenous Leukemia)
03/2015 - 04/2001
2Hypersensitivity (Allergy)
07/2014 - 12/2001
2Infections
05/2014 - 11/2000
2Precursor Cell Lymphoblastic Leukemia-Lymphoma (Acute Lymphoblastic Leukemia)
03/2013 - 12/2012
2Colitis
10/2003 - 04/2003
2Vasculitis (Vasculitides)
09/2002 - 11/2001
2Pneumonia (Pneumonitis)
07/2001 - 04/2001
2Glioma (Gliomas)
06/2001 - 03/2000
2Squamous Cell Carcinoma (Epidermoid Carcinoma)
12/2000 - 11/2000
1Respiratory Tract Diseases (Respiratory Tract Disease)
01/2016
1Chronic Obstructive Pulmonary Disease (COPD)
01/2016
1Cytokine Release Syndrome
01/2015
1Lung Diseases (Lung Disease)
05/2014
1Respiratory Hypersensitivity
07/2013
1Adenocarcinoma
06/2013
1BCR-ABL Positive Chronic Myelogenous Leukemia (Chronic Myelogenous Leukemia)
03/2013
1Philadelphia Chromosome
03/2013
1T-Cell Lymphoma (Lymphoma, T Cell)
02/2012
1Lymphoma (Lymphomas)
02/2012
1Pancreatic Neoplasms (Pancreatic Cancer)
11/2009
1Experimental Melanoma
11/2009
1Melanoma (Melanoma, Malignant)
11/2009
1Synovitis
04/2008
1Autoimmune Lymphoproliferative Syndrome
10/2007

Drug/Important Bio-Agent (IBA)

24LigandsIBA
01/2016 - 03/2000
20Tumor Necrosis Factor-alpha (Tumor Necrosis Factor)IBA
01/2016 - 08/2000
12Monoclonal AntibodiesIBA
11/2009 - 03/2000
8Fas Ligand Protein (Fas Ligand)IBA
10/2003 - 03/2000
7CytokinesIBA
01/2015 - 04/2001
7Interleukin-12 (IL 12)IBA
07/2013 - 01/2000
6TNF-Related Apoptosis-Inducing LigandIBA
03/2013 - 11/2000
5AntigensIBA
07/2014 - 03/2001
4Death Domain ReceptorsIBA
03/2013 - 12/2006
3Therapeutic UsesIBA
09/2014 - 04/2003
3ChemokinesIBA
11/2009 - 08/2001
3alpha-galactosylceramideIBA
10/2002 - 03/2001
3OX40 LigandIBA
02/2001 - 01/2000
2Proteins (Proteins, Gene)FDA Link
03/2015 - 01/2000
2FibrinolysinFDA Link
01/2015 - 02/2012
2AllergensIBA
09/2014 - 07/2013
2Immunoglobulin G (IgG)IBA
07/2014 - 03/2000
2Immunoglobulins (Immunoglobulin)IBA
07/2014 - 11/2001
2Immunoglobulin E (IgE)IBA
07/2014 - 09/2002
2Neutralizing AntibodiesIBA
05/2014 - 02/2012
2Myelin-Oligodendrocyte GlycoproteinIBA
11/2012 - 01/2000
2Pharmaceutical PreparationsIBA
02/2012 - 11/2000
2Matrix Metalloproteinases (MMPs)IBA
02/2012 - 11/2000
2Intercellular Signaling Peptides and Proteins (Growth Factors)IBA
02/2012 - 03/2000
2DNA (Deoxyribonucleic Acid)IBA
11/2009 - 03/2000
2ThyroglobulinFDA Link
12/2008 - 12/2001
2NF-kappa B (NF-kB)IBA
01/2008 - 11/2001
2CaspasesIBA
01/2008 - 03/2000
2AntibodiesIBA
12/2006 - 01/2000
2InterleukinsIBA
12/2006 - 03/2001
2Tumor Necrosis Factor Receptors (Tumor Necrosis Factor Receptor)IBA
09/2003 - 12/2001
2Mercuric Chloride (Sublimate)IBA
09/2002 - 11/2001
2InterferonsIBA
12/2001 - 03/2001
2IntegrinsIBA
05/2001 - 04/2001
24-1BB Ligand (4 1BB Ligand)IBA
05/2001 - 12/2000
2LipopolysaccharidesIBA
05/2001 - 11/2000
2PerforinIBA
04/2001 - 01/2001
2Peptides (Polypeptides)IBA
02/2001 - 01/2000
2KB R7785IBA
11/2000 - 08/2000
1SmokeIBA
01/2016
1Messenger RNA (mRNA)IBA
01/2016
1Vascular Endothelial Growth Factor Receptor-2 (Vascular Endothelial Growth Factor Receptor 2)IBA
06/2013
1Imatinib Mesylate (Gleevec)FDA Link
03/2013
1Dasatinib (BMS 354825)FDA Link
03/2013
1Tyrosine Kinase InhibitorsIBA
03/2013
1Small Interfering RNA (siRNA)IBA
03/2013
1nilotinibFDA Link
03/2013
1Stem Cell FactorIBA
02/2012
1Antifibrinolytic Agents (Antifibrinolytics)IBA
02/2012
1PlasminogenIBA
02/2012
1EnzymesIBA
02/2012
1Chemokine CCL5IBA
11/2009
1Complementary DNA (cDNA)IBA
11/2009
1Vaccine AdjuvantsIBA
11/2009
1Fibroblast Growth Factors (Fibroblast Growth Factor)IBA
04/2008
1Intercellular Adhesion Molecule-1 (Intercellular Adhesion Molecule 1)IBA
04/2008
1Reactive Oxygen Species (Oxygen Radicals)IBA
01/2008
1fas Receptor (CD95 Antigen)IBA
10/2007

Therapy/Procedure

9Therapeutics
01/2016 - 01/2000
3Immunotherapy
09/2014 - 12/2001
2Stem Cell Transplantation
03/2013 - 12/2012
2Transplantation
11/2012 - 05/2006
2Bone Marrow Transplantation (Transplantation, Bone Marrow)
08/2000 - 04/2000
1Oral Administration
07/2014